Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report

First Page		Document Content
Complement system Acquired hemolytic anemia Nephrology Hematopathology Hemolytic-uremic syndrome Syndromes Alexion Pharmaceuticals Factor H Complement factor I Anatomy Medicine Hematology		Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report Add to Reading List Source URL: www.jmedicalcasereports.com Download Document from Source Website File Size: 634,04 KB Share Document on Facebook

	Insights into hypertension in children and adolescents in (South) Africa: the role of salt sensitivity Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town DocID: 1vj68 - View Document
	Visterra to Present New Preclinical Results on VIS649, its Antibody for the Treatment of IgA Nephropathy, at the American Society of Nephrology Kidney Week Conference - VIS649 Reduced Serum IgA, with Favorable Safety Pro DocID: 1uEgV - View Document
	conferenceseries.com 9th International Conference on Nephrology: Kidney & Therapeutics September 29-30, 2016 Orlando, USA DocID: 1uvE8 - View Document
	Visterra to Present New Preclinical Results on VIS649, its Antibody for the Treatment of IgA Nephropathy, at the American Society of Nephrology Kidney Week Conference - VIS649 Reduced Serum IgA, with Favorable Safety Pro DocID: 1uvxq - View Document
	NRMP SMS Nephrology Match for Appointment Year 2016–2017: ASN Brief Analysis Kurtis Pivert, ASN Content and Media Analyst On December 2, 2015, the National Resident Matching Program (NRMP) released preliminary results DocID: 1tmLJ - View Document